Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Strong Liquidity ⢠Dilution Risk ARQT's strong quarterly profitability, cash flow, and liquidity recovery are offset by elevated valuation, substantial working-capital exposure, debt, and dilution risk.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Oversold momentum ⢠Support test Support Level: $23.66â$23.75 Resistance Level: $24.87â$25.14 ARQT is in a last-month downtrend below its moving average, with $23.66â$23.75 support at risk and a recovery above $24.87â$25.14 needed to improve momentum.
Sentiment & News
Key News Insights: ⢠Revenue acceleration ⢠Raised guidance ⢠Pediatric expansion Arcutis' strong ZORYVE growth, raised guidance, profitability progress, and expanded pediatric pipeline support a positive outlook.
AI Summary
ARQT has transitioned into a cash-generative commercial-stage story driven by ZORYVE's rapid growth and high operating leverage, but its premium valuation leaves little tolerance for any slowdown in the single-franchise engine; investors should prioritize prescription trends, payer access, and sustained cash conversion over headline earnings.
Description
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company developing topical treatments for dermatological conditions. Its lead asset is a roflumilast cream that has completed Phase III trials for plaque psoriasis and atopic dermatitis, and its pipeline includes additional roflumilast and topical JAK1 inhibitor formulations targeting scalp and skin disorders such as seborrheic dermatitis, hand eczema, vitiligo and alopecia areata. The company was incorporated in 2016, changed its name in October 2019, and is headquartered in Westlake Village, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 4 | Mar 11 | ARQT | Arcutis Biotherapeutics, Inc. | Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels. | Closed | -0.7% |
| Dec 2 | Dec 9 | ARQT | Arcutis Biotherapeutics, Inc. | Compelling short-term growth supported by strong Q3 revenue growth (+122% YoY), recent FDA pediatric approvals, upcoming Phase 2 topline data in Q1 2026, solid profitability trends, strong liquidity with $191M cash, and a 20% price surge with bullish technical momentum. | Closed | +1.1% |